However, these associations may also be subject to reverse causality or confounding by disease activity and progression, as higher CHI3L1 levels may reflect underlying MS severity rather than a direct effect of vitamin D. Vitamin D emerges as a uniquely positioned therapeutic agent within this context. The gene discussed is CHI3L1; the disease is myeloid sarcoma.